Some breast cancer tumors may be resistant to a common chemotherapy treatment

March 27, 2012 in Cancer

Some breast cancer tumours may be resistant to a common chemotherapy treatment, suggests recent medical research at the University of Alberta.

Principal investigator Ing Swie Goping and her team discovered some breast had low levels of certain , and that those tumours didn't respond well to taxane , a common treatment used in breast cancer.

"These tumours didn't shrink and were resistant to a common . These results give us a strong incentive to continue our research," she said.

Goping and her team looked at tumour samples from 24 patients who had breast cancer. These patients were treated with chemotherapy before surgery. The team discovered four genes in the 'survival' system of tumour cells weren't functioning well in some of the samples. When parts of this system don't work the way they are supposed to, the tumour survival system gets weaker.

Researchers expected that because this survival system was weaker in some tumours, that chemotherapy treatment would be more effective at shrinking these tumours. But the opposite happened.

Instead, they found that the stronger the tumours' survival system was, the better the chemotherapy worked.

"This discovery was a bit of a surprise," said Goping, a researcher in both the Department of Biochemistry and the Department of Oncology.

"One would expect that with strong survival systems would be more chemotherapy-resistant, but that's not what we discovered."

Goping noted this research was purely curiosity-driven, and the finding underscores the importance of basic research.

"It was a question we were asking at a very basic level and it turns out the discovery could be clinically relevant. At the moment there is no tool to determine which women would be good candidates for taxane chemotherapy. And chemotherapy resistance is a major clinical problem."

Goping hopes to continue this research by examining tumour samples from thousands of patients over a span of at least three years, in hopes of confirming what the team discovered is indeed a 'marker' that will predict which breast cancer patients will respond well to taxane chemotherapy.

She noted it would be years before doctors would be able to actually start testing patients for this marker.

More information: The study was published in the peer-reviewed journal Oncogene.

Journal reference: Oncogene search and more info website

Provided by University of Alberta search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Research identifies a way to make cancer cells more responsive to chemotherapy

Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...

Cancer created 5 hours ago | popularity 5 / 5 (2) | comments 0

Mayo Clinic genomic analysis lends insight to prostate cancer

Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...

Cancer created 5 hours ago | popularity not rated yet | comments 0

When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs

Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...

Cancer created 6 hours ago | popularity not rated yet | comments 0 | with audio podcast

Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity

Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...

Cancer created 10 hours ago | popularity not rated yet | comments 0

Protein preps cells to survive stress of cancer growth and chemotherapy

Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.

Cancer created 10 hours ago | popularity not rated yet | comments 0 | with audio podcast


Controlling mood through the motions of mitochondria

(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...

Multiple research teams unable to confirm high-profile Alzheimer's study

Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.

Scientists discover molecule triggers sensation of itch

Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...

Motion quotient: IQ predicted by ability to filter motion (w/ video)

A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...

Researchers find common childhood asthma unconnected to allergens or inflammation

Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...

Diabetes' genetic underpinnings can vary based on ethnic background, studies say

Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.